Skip to content
To the full analysis

Sanara MedTech Stock: Valuation and P/E

SMTI
$32.67Closing price of 19 Nov 2026MEQIRI Score 61 out of 100

Here you can see what Sanara MedTech Inc. costs today relative to earnings, sales and book value, and how that compares with its own valuation history. A high P/E is not a verdict by itself; what matters is whether it sits above or below what the market usually grants this company.

Daily figure as of 20 Nov 2026

P/E
Loss
includes one-off items
P/S
2.7
P/B
37.43
PEG
no data

Why There Is No P/E

Sanara MedTech made a loss of $0.36 per share over the last twelve months, so there is no P/E. The last profitable fiscal year was 2017, with a P/E of 35.3 at the time. 9 of the last 10 fiscal years ended in a loss. Without earnings, the price-to-sales ratio helps: Sanara MedTech is valued at 2.7 times its revenue of the last twelve months.

Against Its Own Valuation History

Each fiscal year is shown with its P/E on the year-end date, using the price at the time.

There is no reliable data on this for this company.

P/E of Industry Peers

StockP/EOwn median
Kestra Medical Technologiesno datano data
STAAR Surgical2,429.889.2
Gerresheimerno data23.5
Safilo Group18.716.7
Dynavox Group29.346.3
AngioDynamicsno data29.6
Embecta4.19.6
COLTENE Holding19.121.3
Sanara MedTechno data35.3

The eight peers closest in market value, largest first. Trailing twelve-month P/E as of 20 Nov 2026, loss makers have none.

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
  • Price: closing price of 19 Nov 2026
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.